Oxford, UK: 2 July 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy company, and Sigma-Aldrich, a leading life science and high technology company, today announced that they have signed a joint licence agreement for the LentiVector technology with a major US-based biotechnology company, which provides the company with access to the technology for global research activities. Sigma-Aldrich is Oxford BioMedica’s strategic partner and exclusive licensee in the commercialisation of the LentiVector technology for research use. Financial details were not disclosed.
